Skip to main content
. 2019 Mar 4;16(3):e1002756. doi: 10.1371/journal.pmed.1002756

Fig 4. Projected impact of HPV vaccination in MSM.

Fig 4

The model-averaged population prevalence of anal HPV16 infection among MSM by vaccination scenario with 90% prediction intervals (dotted lines), under (A) base-case and (B) improved HPV vaccine uptake in targeted vaccination. In both panels, the combined strategy of vaccination at the age of 12 years with 40% uptake together with a targeted campaign among all MSM with base-case uptake is shown for comparison. HPV, human papillomavirus; HPV16, human papillomavirus genotype 16; MSM, men who have sex with men.